Compare Seagate Technology Holdings PLC (STX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Seagate Technology Holdings PLC vs Viatris Inc — how do they compare? Seagate Technology Holdings PLC trades at $772.95 (market cap $176.19B), while Viatris Inc trades at $17.52 (market cap $20.03B). The key difference: Seagate Technology Holdings PLC is far larger — about 8.8× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Seagate Technology Holdings PLC for 41 Days and Viatris Inc for 57 Days on average.
| STX | VTRS | |
|---|---|---|
Market Cap | $176.19B | $20.03B |
Volume | 5,061,875 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $1.09K | $18.27 |
52-Week Low | $211.63 | $9.74 |
Typical Hold Time | 41 Days | 57 Days |
Enterprise Value | $178.34B | $32.15B |
Dividend Yield | 0.38% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Seagate Technology (STX) trades at $807.34, up 0.21% with recent volatility driven by AI storage competition concerns. The stock shows strong profitability with 26.11% net margin and 371.53% ROE, though valuation ratios appear elevated (P/E 55.74, P/B 81.31). Recent earnings consistently beat expectations, with Q2 2026 EPS of $5.71 surpassing the $5.10 estimate. Technical indicators show bearish momentum with support at $794 and resistance at $816.
Outlook remains cautiously optimistic given strong AI-driven storage demand and analyst consensus price target of $1,130. Key risks include increased competition from Toshiba's planned production expansion and potential margin compression. The company's negative shareholder equity and high debt levels warrant monitoring, though projected 2026 revenue growth to $12.2B with $3.2B net income suggests continued operational strength.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
